Perioperative levosimendan therapy is associated with a lower incidence of acute kidney injury after cardiac surgery: A meta-analysis

Journal of Cardiovascular Pharmacology

Volumn 63, Issue 2, 2014, Pages 107-112

  Niu, Zhao Zhuo ^a,b   Wu, Shu Ming ^a   Sun, Wen Yu ^a   Hou, Wen Ming ^b   Chi, Yi Fan ^b  

^a SHANDONG UNIVERSITY   (China)

^b QINGDAO MUNICIPAL HOSPITAL   (China)

Author keywords

Acute kidney injury; Cardiac surgery; Complications; Levosimendan; Outcomes

Indexed keywords

ACUTE KIDNEY INJURY; ADULT; CARDIAC SURGICAL PROCEDURES; CARDIOTONIC AGENTS; HUMANS; HYDRAZONES; INCIDENCE; PERIOPERATIVE CARE; PYRIDAZINES; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84894093173     PISSN: 01602446     EISSN: 15334023     Source Type: Journal    
DOI: 10.1097/FJC.0000000000000028     Document Type: Article

References (52)

1. Mangano CM, Diamondstone LS, Ramsay JG, et al. Renal dysfunction after myocardial revascularization: Risk factors, adverse outcomes, and hospital resource utilization. The Multicenter Study of Perioperative Ischemia Research Group. Ann Intern Med. 1998;128:194-203
2. Tuttle KR, Worrall NK, Dahlstrom LR, et al. Predictors of ARF after cardiac surgical procedures. Am J Kidney Dis. 2003;41:76-83
3. Conlon PJ, Stafford-Smith M, White WD, et al. Acute renal failure following cardiac surgery. Nephrol Dial Transplant. 1999;14:1158-1162
4. Chertow GM, Levy EM, Hammermeister KE, et al. Independent association between acute renal failure and mortality following cardiac surgery. Am J Med. 1998;104:343-348
5. Ryckwaert F, Boccara G, Frappier JM, et al. Incidence, risk factors, and prognosis of a moderate increase in plasma creatinine early after cardiac surgery. Crit Care Med. 2002;30:1495-1498
6. Thakar CV, Arrigain S, Worley S, et al. A clinical score to predict acute renal failure after cardiac surgery. J Am Soc Nephrol. 2005;16:162-168
7. Wan S, LeClerc JL, Vincent JL. Inflammatory response to cardiopulmonary bypass: Mechanisms involved and possible therapeutic strategies. Chest. 1997;112:676-692
8. Kivikko M, Lehtonen L. Levosimendan: A new inodilatory drug for the treatment of decompensated heart failure. Curr Pharm Des. 2005;11: 435-455
9. Michaels AD, McKeown B, Kostal M, et al. Effects of intravenous levosimendan on human coronary vasomotor regulation, left ventricular wall stress and myocardial oxygen uptake. Circulation. 2005;111:1504-1509
10. Follath F, Cleland JG, Just H, et al; Steering Committee and Investigators of the Levosimendan Infusion versus Dobutamine (LIDO) Study. Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output cardiac failure (the LIDO study): A randomized doubleblind trial. Lancet. 2002;360:196-202
11. Moiseyev VS, Pãuder P, Andrejevs N, et al; RUSSLAN Study Investigators. Safety and efficacy of a novel calcium sensitizer, levosimendan in patients with left ventricular failure due to an acute myocardial infarction. A randomized, placebo-controlled, double-blind study (RUSSLAN). Eur Heart J. 2002;23:1422-1432
12. Pollesello P, Ovaska M, Kaivola J, et al. Binding of a new Ca2+ sensitizer, levosimendan, to recombinant human cardiac troponin C. A molecular modeling, fluorescence probe, and proton nuclear magnetic resonance study. J Biol Chem. 1994;269:28584-28590. [erratum in J Biol Chem. 1995;270(6):2880
13. Haikala H, Linden IB. Mechanisms of action of calcium-sensitizing drugs. J Cardiovasc Pharmacol. 1995;26(suppl 1):S10-S19
14. Yokoshiki H, Katsube Y, Sunagawa M, et al. Levosimendan, a novel Ca2+ sensitizer, activates the glibenclamide-sensitive K+ channel in rat arterial myocytes. Eur J Pharmacol. 1997;333:249-259
15. Yilmaz MB, Yalta K, Yontar C, et al. Levosimendan improves renal function in patients with acute decompensated heart failure: Comparison with dobutamine. Cardiovasc Drugs Ther. 2007;21:431-435
16. Zager RA, Johnson AC, Lund S, et al. Levosimendan protects against experimental endotoxemic acute renal failure. Am J Physiol Renal Physiol. 2006;290:F1453-F1462
17. Biondi-Zoccai GG, Agostoni P, Abbate A, et al. A simple hint to improve Robinson and Dickersins highly sensitive PubMed search strategy for controlled clinical trials. Int J Epidemiol. 2005;34:224-225
18. Higgins JPT, Green S. Cochrane Handbook for Systematic Reviews of Interventions 4.2.5. Chichester, United Kingdom: John Wiley & Sons, Ltd; 2005
19. Moher D, Cook DJ, Eastwood S, et al. Improving the quality of reports of meta-Analyses of randomized controlled trials: The QUOROM Statement. Quality of Reporting of Meta-Analyses. Lancet. 1999;354: 1896-1900
20. Biondi-Zoccai GG, Lotrionte M, Abbate A, et al. Compliance with QUOROM and quality of reporting of overlapping meta-Analysis on the role of acetylcysteine in the prevention of contrast associated nephropathy: Case study. BMJ. 2006;332:202-209
21. Akselrod B, Trekova N, Tolstova I, et al. Preoperative levosimendan administration: What is the vascular payment during anaesthesia?. J Cardiothorac Vasc Anesth. 2010;24:S18-S19
22. Alvarez J, Bouzada M, Fernàndez AL, et al. Hemodynamic effects of levosimendan compared with dobutamine in patients with low cardiac output after cardiac surgery [in Spanish]. Rev Esp Cardiol. 2006;59: 338-345
23. Alvarez J, Taboada M, Rodríguez J, et al. Hemodynamic effects of levosimendan following cardiac surgery [in Spanish]. Rev Esp Anestesiol Reanim. 2005;52:389-394
24. Barisin S, Husedzinovic I, Sonicki Z, et al. Levosimendan in off-pump coronary artery bypass: A four-Times masked controlled study. J Cardiovasc Pharmacol. 2004;44:703-708
25. Chamos C, Daidou T, Delis E, et al. The effects of levosimendan compared with milrinone in cardiac surgery patients. J Cardiothorac Vasc Anesth. 2009;26:S19-S20
26. De Hert SG, Lorsomradee S, Cromheecke S, et al. The effects of levosimendan in cardiac surgery patients with poor left ventricular function. Anesth Analg. 2007;104:766-773
27. Eriksson HI, Jalonen JR, Heikkinen LO, et al. Levosimendan facilitates weaning from cardiopulmonary bypass in patients undergoing coronary artery bypass grafting with impaired left ventricular function. Ann Thorac Surg. 2009;87:448-454
28. Husedzinovi-c I, Barisin S, Bradi-c N, et al. Levosimendan as a new strategy during off-pump coronary artery bypass grafting: Double-blind randomized placebo-controlled trial. Croat Med J. 2005;46:950-956
29. Järvelä K, Maaranen P, Sisto T, et al. Levosimendan in aortic valve surgery: Cardiac performance and recovery. J Cardiothorac Vasc Anesth. 2008;22:693-698
30. Jörgensen K, Bech-Hanssen O, Houltz E, et al. Effects of levosimendan on left ventricular relaxation and early filling at maintained preload and afterload conditions after aortic valve replacement for aortic stenosis. Circulation. 2008;117:1075-1081
31. Knez I, Schweiger S, Ovcina I. Effects of Ca2+ sensitizer levosimendan on flow in internal thoracic and radial arteries in patients undergoing CABG-Preliminary results. Eur Heart J. 2005;26:527
32. Leppikangas H, Tenhunen JJ, Lindgren L, et al. Effects of levosimendan on indocyanine green plasma disappearance rate and the gastric mucosalarterial pCO2 gradient in abdominal aortic aneurysm surgery. Acta Anaesthesiol Scand. 2008;52:785-792
33. Leppikangas H, Järvelä K, Sisto T, et al. Preoperative levosimendan infusion in combined aortic valve and coronary bypass surgery. Br J Anaesth. 2011;106:298-304
34. Lilleberg J, Nieminen MS, Akkila J, et al. Effects of a new calcium sensitizer, levosimendan, on haemodynamics, coronary blood flow and myocardial substrate utilization early after coronary artery bypass grafting. Eur Heart J. 1998;19:660-668
35. Nijhawan N, Nicolosi AC, Montgomery MW, et al. Levosimendan enhances cardiac performance after cardiopulmonary bypass: A prospective, randomized placebo-controlled trial. J Cardiovasc Pharmacol. 1999;34: 219-228
36. Tritapepe L, De Santis V, Vitale D, et al. Preconditioning effects of levosimendan in coronary artery bypass grafting-A pilot study. Br J Anaesth. 2006;96:694-700
37. Al-Shawaf E, Ayed A, Vislocky I, et al. Levosimendan or milrinone in the type 2 diabetic patient with low ejection fraction undergoing elective coronary artery surgery. J Cardiothorac Vasc Anesth. 2006; 20:353-357
38. Lahtinen P, Pitkänen O, Pölönen P, et al. Levosimendan reduces heart failure after cardiac surgery: A prospective, randomized, placebo-controlled trial. Crit Care Med. 2011;39:2263-2270
39. Levin RL, Degrange MA, Porcile R, et al. The calcium sensitizer levosimendan gives superior results to dobutamine in postoperative low cardiac output syndrome [in Spanish]. Rev Esp Cardiol. 2008;61:471-479
40. Tritapepe L, De Santis V, Vitale D, et al. Levosimendan pre-Treatment improves outcomes in patients undergoing coronary artery bypass graft surgery. Br J Anaesth. 2009;102:198-204
41. Ristikankare A, Pöyhiä R, Eriksson H, et al. Effects of levosimendan on renal function in patients undergoing coronary artery surgery. J Cardiothorac Vasc Anesth. 2012;26:591-595
42. Rosner MH, Okusa MD. Acute kidney injury associated with cardiac surgery. Clin J Am Soc Nephrol. 2006;1:19-32
43. Karkouti K, Wijeysundera DN, Yau TM, et al. Acute kidney injury after cardiac surgery: Focus on modifiable risk factors. Circulation. 2009;119: 495-502
44. Abraham VS, Swain JA. Cardiopulmonary bypass and the kidney. In: Gravlee GP, Davis RF, Kurusz M, et al, eds. Cardiopulmonary Bypass: Principles and Practice. 2nd ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2000:382-391
45. Pompermayer K, Souza DG, Lara GG, et al. The ATP-sensitive potassium channel blocker glibenclamide prevents renal ischemia/reperfusion injury in rats. Kidney Int. 2005;67:1785-1796
46. Faivre V, Kaskos H, Callebert J, et al. Cardiac and renal effects of levosimendan, arginine vasopressin, and norepinephrine in lipopolysaccharidetreated rabbits. Anesthesiology. 2005;103:514-521
47. Mullens W, Abrahams Z, Francis GS, et al. Importance of venous congestion for worsening of renal function in advanced decompensated heart failure. J Am Coll Cardiol. 2009;53:589-596
48. Zorlu A, Yücel H, Yontar OC, et al. Effect of levosimendan in patients with severe systolic heart failure and worsening renal function. Arq Bras Cardiol. 2012;98:537-543
49. Pataricza J, Krassói I, Höhn J, et al. Functional role of potassium channels in the vasodilating mechanism of levosimendan in porcine isolated coronary artery. Cardiovasc Drugs Ther. 2003;17:115-121
50. Parissis JT, Farmakis D, Kremastinos DT. Anti-inflammatory effects of levosimendan in decompensated heart failure: Impact on weight loss and anemia. Am J Cardiol. 2005;95:923-924
51. Singh BN, Lilleberg J, Sandell EP, et al. Effects of levosimendan on cardiac arrhythmia: Electrophysiologic and ambulatory electrocardiographic findings in phase II and phase III clinical studies in cardiac failure. Am J Cardiol. 1999;83:16-20
52. Givertz MM, Andreou C, Conrad CH, et al. Direct myocardial effects of levosimendan in humans with left ventricular dysfunction: Alteration of force-frequency and relaxation-frequency relationships. Circulation. 2007;115:1218-1224